Boston Scientific Warns of Challenges in 2027
Boston Scientific cited pricing pressure in China and weakness in its cardiac devices business as reasons for the warning.
Related stories
Imerys Raises FY 2026 Adjusted EBITDA Target to €570–€590 Million
M impact | EARNINGS | Oct 29, 2026, 04:56 PM UTC
D.R. Horton FY2026 Revenue Falls 4%, Net Income Drops 19%
D.R. Horton reported fiscal 2026 revenue of $33.0 billion, down 4% year over year, and net income of $2.9 billion, down 19%. Diluted EPS fell 13% to $10.11. Fourth-quarter revenue
M impact | EARNINGS | Oct 29, 2026, 04:53 PM UTC
Manitou Confirms 2026 Revenue Growth Outlook of 6.5%-8.0%
Manitou confirmed its 2026 revenue growth outlook at 6.5%-8.0%.
M impact | EARNINGS | Oct 29, 2026, 04:53 PM UTC
Manitou Confirms Revenue Growth Outlook for 2026
Manitou confirmed its revenue growth outlook for 2026.
M impact | EARNINGS | Oct 29, 2026, 04:53 PM UTC
INSUR Reports Nine-Month Net Profit of €18.5 Million
M impact | EARNINGS | Oct 29, 2026, 04:51 PM UTC
INSUR Reports Nine-Month Revenue of €96.0 Million
M impact | EARNINGS | Oct 29, 2026, 04:51 PM UTC